Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2021

View Archived Issues

Ascentage Pharma polycomb protein EED inhibitor displays potency, tumor regression potential

FPR2 agonist NAP-1051 shows promise in preclinical SLE model

SCO-spondin-derived peptide shows neuroprotection and increased synaptic transmission in the CNS

Calreticulin as promising new therapeutic target in breast cancer

PharmaMar describes HER2-targeting antibody-drug conjugates

New MAP4K1 inhibitors discovered at Wigen Biomedicine Technology

Roche patents potassium voltage-gated channel subfamily C member 1 activators

New compounds inhibiting respiratory syncytial virus identified at Janssen

Boehringer Ingelheim presents new HER2 inhibitors

COVA1-18 demonstrates strong antiviral activity against SARS-CoV-2 in vivo

DDR1 promotes immune exclusion in tumors and it is a therapeutic target

Cannabigerol derivatives have anti-inflammatory, analgesic and antiobesity potential

Circulating levels of galectin-1 associated with lower kidney function

Rakovina presents data on in vitro activity of novel dual PARP-HDAC inhibitors

Study shows gut microbiome changes may be effect, not cause, of autism spectrum disorders

Opus Genetics licenses new preclinical program for inherited retinal disease

ITIH4 is a marker for early diagnosis of gastric cancer

Fitness cost of antibiotic-resistant mutants can be used to identify new combination therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...